Back to Search Start Over

AstraZeneca jettisons two heart drugs to Cheplapharm in $400m deal

Source :
Legal Monitor Worldwide. October 31, 2020
Publication Year :
2020

Abstract

AstraZeneca is set to sell the rights to its AT1 subtype angiotensin II receptor antagonist Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) to [...]

Subjects

Subjects :
Angiotensin II
Drug approval
Cardiovascular agents
Hydrochlorothiazide
Business, international
Law
Atacand (Medication)

Details

Language :
English
Database :
Gale General OneFile
Journal :
Legal Monitor Worldwide
Publication Type :
News
Accession number :
edsgcl.640014800

Tools

Authors Abstract Subjects Details